- Drugs
- Surgery
- Oxygen Therapy
- Others
Chronic Obstructive Pulmonary Disease (COPD) Market was valued at USD 21.2 billion in 2022 and is poised to grow at a CAGR of 4.8% over 2023-2029. Chronic obstructive pulmonary disease (COPD) is a type of progressive lung disease characterized by long-term respiratory symptoms and airflow limitation, including symptoms such as shortness of breath and a cough, and the causes include tobacco smoking, air pollution, and genetics. Based on the drug class, the combination therapy segment is anticipated to dominate the market share over the forecast period. According to the World Health Organization, COPD is the third leading cause of death worldwide, causing 3.23 million deaths in 2019. The increasing incidences of respiratory disorders and growing awareness will act as the chronic obstructive pulmonary disease market growth driver, whereas, the high cost of treatment would be the lagging factor for the market. The rise in chronic obstructive pulmonary disease market demand for novel drug therapies and an increase in investments by key market players are opportunities for the expansion of the market.
Chronic Obstructive Pulmonary Disease (COPD) Market Key Developments:
- In Oct 2021, Mylan Pharmaceuticals received FDA approval for its investigational new drug application for Breyna (Budesonide and Formoterol fumarate dihydrate inhalation aerosol), for the treatment of asthma and COPD.
- In April 2022, GSK launched Trelegy Ellipta, a single-inhaler triple therapy for COPD patients.
Chronic Obstructive Pulmonary Disease Market Summary
Study Period
2023-29
Base Year
2022
CAGR
4.8%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Chronic Obstructive Pulmonary Disease (COPD) Market Dynamics
With an increase in the incidence of COPD, awareness programs, and adoption of effective treatments are also increasing, so the advancements in technologies for drug development are the major factors for the market growth. For instance, in Feb 2021, Sanofi, in collaboration with Regeneron Pharmaceuticals, initiated a phase-III clinical trial for Itepekimab, in moderate-to-severe COPD. Thus, the increased awareness, research, and development for chronic disorders will lead to the growth of the market within the forecast period. However, side effects and risks associated with COPD drugs could be a negative factor for the market growth.
North-America Got Significant Share of
Chronic Obstructive Pulmonary Disease (COPD) Market Regional Analysis
Chronic Obstructive Pulmonary Disease (COPD) market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to the Center for Disease Control and Prevention 2020, the percentage of COPD for adults aged 18 and over in the USA in 2020 was 5%. According to the National Center for Biotechnology Information’s article published in 2022, the estimated prevalence of COPD was 11.1% in South Asian countries. The North America Chronic Obstructive Pulmonary Disease (COPD) market is expected to dominate the market over the forecast period, majorly because of the highly developed healthcare systems in the United States and Canada, as well as the strong presence of major market players, and increased in the number of smokers in the region. Additionally, Asia Pacific is projected to experience growth in the COPD market owing to the rise in the geriatric population.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The chronic obstructive pulmonary disease (COPD) market report provides granular level information about the market size, regional market share, historic market (2018-2022) and forecast (2023-2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Chronic Obstructive Pulmonary Disease Market Segmentation
By Treatment
By Drug Class
- Combination Therapy
- Bronchodilators
- Corticosteroids
- Phosphodiesterase Type 4 Inhibitor
- Mucokinetics
- Others
By Disease Type
- Chronic Bronchitis
- Emphysema
By End User
- Hospitals
- Clinics
- Homecare
- Others
Frequently Asked Questions
The Chronic Obstructive Pulmonary Disease (COPD) market was valued at USD 21.2 billion in 2022 and is expected to grow at a 4.8% CAGR over the forecast period 2023 – 2029.
The rise in demand for novel drug therapies and an increase in investments are the key opportunities for the Chronic Obstructive Pulmonary Disease (COPD) market.
The increasing incidences of respiratory disorders and growing awareness are the growth drivers in the Chronic Obstructive Pulmonary Disease (COPD) market.
Boehringer Ingelheim International GmbH, GlaxoSmithKline plc., Novartis International AG, AstraZeneca, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Merck & Co., Amneal Pharmaceuticals LLC., Mylan N.V., and OptiNose US Inc. are a few companies operating in the Chronic Obstructive Pulmonary Disease (COPD) market.
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline plc.
- Novartis International AG
- AstraZeneca
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Merck & Co.
- Amneal Pharmaceuticals LLC.
- Mylan N.V.
- OptiNose US Inc.